Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.73 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.73 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.59 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.59 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.54 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | GK | P32189 | 1/20 | 0.53 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946398 | 1.00 | P2RX3 (0.73) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL14853949 | 0.95 | P2RX3 (0.67) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL18574267 | 0.91 | P2RX3 (0.78) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL16340735 | 0.91 | P2RX3 (0.78) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL14948867 | 0.91 | P2RX3 (0.78) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL14929351 | 0.91 | P2RX3 (0.58) | P2RX3P2RX2NT5EP2RY1P2RY12 | |
| SCHEMBL14946384 | 0.91 | P2RX3 (0.58) | P2RX3P2RX2NT5EP2RY1P2RY12 | |
| SCHEMBL14946381 | 0.91 | P2RX3 (0.78) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL14946188 | 0.89 | P2RX3 (0.76) | P2RX3P2RX2GPR17NT5EP2RX4 | |
| SCHEMBL11267406 | 0.88 | P2RX3 (0.65) | P2RX3P2RX2GPR17NT5EP2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RX3 736/4885P2RX2 904/4885GPR17 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.